2009 DRUG RECALL DATA ANALYZED BY DOSAGE FORM
This article was originally published in The Gold Sheet
The following is an analysis by dosage form of the data on drug recalls included in FDA "Enforcement Reports" during 2009. The chart includes the number of products recalled for each dosage form by market type (Rx vs. OTC), problem area and recall class. [EDITOR'S NOTE: See the head note of "Drug Product Recalls In 2009: Categorized By Problem Area" for more information on the recall data and categories.]
You may also be interested in...
The information on drug product recalls in the following pages has been collected and categorized by "The Gold Sheet" from FDA "Enforcement Reports" issued during calendar year 2009.
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.